TrialLeukemia & lymphoma2023

A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.

Sarit Assouline et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.